Institute for Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Institute for Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69K	Buy	+10	New	+$1.48K	﹤0.01%	1613

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Institute for Wealth Management's NBIX Position: Q2 2026 in Review

Institute for Wealth Management opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 10 shares worth $1.69K. The stake represents ﹤0.01% of the portfolio and ranks #1613 among its holdings.

420 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Institute for Wealth Management held 10 shares of Neurocrine Biosciences worth $1.69K as of Q2 2026.
Neurocrine Biosciences was a new Institute for Wealth Management position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Institute for Wealth Management's portfolio in Q2 2026, its #1613 holding.
420 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Institute for Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.